I am a
Home I AM A Search Login

Papers of the Week

Papers: 10 Dec 2022 - 16 Dec 2022

Human Studies, Pharmacology/Drug Development

2022 Dec 10

Int J Dermatol

Brodalumab: Efficacy, safety, and survival in mid-term (52 weeks) on real clinical practice in Andalucia, Spain.


Galan-Gutierrez M, Font-Ugalde P, Padial E, Hernandez-Montoya C, Godoy D, Armario-Hita JC, Ruiz-Villaverde R
Int J Dermatol. 2022 Dec 10.
PMID: 36495585.


Brodalumab is a recombinant monoclonal antibody (IgG2) that binds with high affinity to the human interleukin-17 (IL-17) receptor A and blocks the biological activity of the proinflammatory cytokines IL-17A, IL-17F, IL-17A/F heterodimer, and IL- 25, resulting in inhibition of inflammation and clinical symptoms associated with psoriasis. Its introduction has managed to increase the levels of efficacy, safety (improving that previously presented by the anti-IL-17 class), and survival.